Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL W MESHAD

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1538112701
CMS profile
606062
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,677.09

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,601.10 100
Education $75.99 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL W MESHAD

NPI 1538112701 · CMS profile ID 606062

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL W MESHAD, NPI 1538112701, CMS profile ID 606062, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1538112701?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $1,677.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $23.0001/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739475595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,265.26 138
PY2020 $1,677.09 101
PY2021 $2,366.84 136
PY2022 $1,734.73 98
PY2023 $1,983.24 96
PY2024 $2,119.59 108
PY2025 $2,149.86 108

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,233,354.80 407
PY2024 Principal investigator $642,244.87 184
PY2023 Principal investigator $530,609.62 245
PY2022 Recipient $10,000.00 12
PY2022 Principal investigator $559,598.18 92
PY2021 Recipient $32.00 1
PY2021 Principal investigator $735,462.12 172
PY2020 Principal investigator $625,066.99 292
PY2019 Principal investigator $972,624.38 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

407 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $564.36 12/31/2025 Non-covered Recipient Entity
Southern Cancer Center SCC
KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II IIIB N2 Non-small Cell No dispute reported 06/30/2026 1232924952
Principal investigator 1 Merck Sharp & Dohme LLC $3,402.83 12/31/2025 Non-covered Recipient Entity
Southern Cancer Center, PC
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232927171
Principal investigator 1 Incyte Corporation $3,375.00 12/29/2025 Non-covered Recipient Entity
SOUTHERN CANCER CTR DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591775
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,835.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753338
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,510.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753340
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754088
Principal investigator 1 Daiichi Sankyo Inc. $64.00 12/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388247
Principal investigator 1 Daiichi Sankyo Inc. $53.00 12/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388249
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388253
Principal investigator 1 Daiichi Sankyo Inc. $54.00 12/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388255
Principal investigator 1 Janssen Research & Development, LLC $7,252.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326905
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388237
Principal investigator 1 Daiichi Sankyo Inc. $42.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388243
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388245
Principal investigator 1 Daiichi Sankyo Inc. $42.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388251
Principal investigator 1 Daiichi Sankyo Inc. $40.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388257
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,835.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753222
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,240.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753336
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $1,620.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753342
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753552
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388239
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388241
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $74,426.18 12/05/2025 Non-covered Recipient Entity
Coastal Pharmacy, Llc
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235997962
Principal investigator 1 Eli Lilly and Company $1,110.00 12/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187890608
Principal investigator 1 Daiichi Sankyo Inc. $2,360.00 11/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387471
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,750.00 11/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185537441
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327596
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328386
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753244
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387469
Principal investigator 1 Epizyme, Inc. $390.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281602
Principal investigator 1 Epizyme, Inc. $390.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281604
Principal investigator 1 Epizyme, Inc. $390.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281606
Principal investigator 1 Daiichi Sankyo Inc. $59.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388227
Principal investigator 1 Daiichi Sankyo Inc. $53.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388229
Principal investigator 1 Daiichi Sankyo Inc. $236.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388231
Principal investigator 1 Daiichi Sankyo Inc. $50.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388233
Principal investigator 1 Daiichi Sankyo Inc. $65.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388235
Principal investigator 1 Epizyme, Inc. $1,125.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281608
Principal investigator 1 Daiichi Sankyo Inc. $54.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388141
Principal investigator 1 Daiichi Sankyo Inc. $301.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388155
Principal investigator 1 Daiichi Sankyo Inc. $54.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388159
Principal investigator 1 Daiichi Sankyo Inc. $450.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388165
Principal investigator 1 Daiichi Sankyo Inc. $54.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388177
Principal investigator 1 Daiichi Sankyo Inc. $64.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388179
Principal investigator 1 Daiichi Sankyo Inc. $61.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388191
Principal investigator 1 Daiichi Sankyo Inc. $66.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388195
Principal investigator 1 Daiichi Sankyo Inc. $70.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388197
Principal investigator 1 Daiichi Sankyo Inc. $64.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388211
Principal investigator 1 Daiichi Sankyo Inc. $236.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388213
Principal investigator 1 Genentech, Inc. $19,949.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680953
Principal investigator 1 Genentech, Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680971
Principal investigator 1 Daiichi Sankyo Inc. $588.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387459
Principal investigator 1 Daiichi Sankyo Inc. $82.60 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387461
Principal investigator 1 Daiichi Sankyo Inc. $1,416.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387463
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388127
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328617
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383858
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383862
Principal investigator 1 Incyte Corporation $956.00 10/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CTR DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591780
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753954
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387455
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387457
Principal investigator 1 Daiichi Sankyo Inc. $412.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387465
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388147
Principal investigator 1 Daiichi Sankyo Inc. $236.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387467
Principal investigator 1 Daiichi Sankyo Inc. $450.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388129
Principal investigator 1 Daiichi Sankyo Inc. $59.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388131
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388133
Principal investigator 1 Daiichi Sankyo Inc. $65.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388135
Principal investigator 1 Daiichi Sankyo Inc. $53.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388137
Principal investigator 1 Daiichi Sankyo Inc. $40.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388139
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388143
Principal investigator 1 Daiichi Sankyo Inc. $40.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388145
Principal investigator 1 Daiichi Sankyo Inc. $65.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388149
Principal investigator 1 Daiichi Sankyo Inc. $900.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388151
Principal investigator 1 Daiichi Sankyo Inc. $51.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388153
Principal investigator 1 Daiichi Sankyo Inc. $66.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388157
Principal investigator 1 Daiichi Sankyo Inc. $987.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388161
Principal investigator 1 Daiichi Sankyo Inc. $66.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388163
Principal investigator 1 Daiichi Sankyo Inc. $66.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388167
Principal investigator 1 Daiichi Sankyo Inc. $66.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388169
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388171
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388173
Principal investigator 1 Daiichi Sankyo Inc. $59.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388175
Principal investigator 1 Daiichi Sankyo Inc. $51.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388181
Principal investigator 1 Daiichi Sankyo Inc. $53.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388183
Principal investigator 1 Daiichi Sankyo Inc. $54.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388185
Principal investigator 1 Daiichi Sankyo Inc. $51.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388187
Principal investigator 1 Daiichi Sankyo Inc. $59.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388189
Principal investigator 1 Daiichi Sankyo Inc. $64.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388193
Principal investigator 1 Daiichi Sankyo Inc. $42.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388199
Principal investigator 1 Daiichi Sankyo Inc. $65.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388201
Principal investigator 1 Daiichi Sankyo Inc. $51.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388203
Principal investigator 1 Daiichi Sankyo Inc. $59.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388205
Principal investigator 1 Daiichi Sankyo Inc. $51.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388207
Principal investigator 1 Daiichi Sankyo Inc. $53.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388209
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388215
Principal investigator 1 Daiichi Sankyo Inc. $65.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388217
Principal investigator 1 Daiichi Sankyo Inc. $53.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388219
Principal investigator 1 Daiichi Sankyo Inc. $64.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388221
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388223
Principal investigator 1 Daiichi Sankyo Inc. $50.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388225
Principal investigator 1 Genentech, Inc. $53.00 10/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680967
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 09/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753942
Principal investigator 1 Genentech, Inc. $1,375.00 09/10/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681278
Principal investigator 1 Genentech, Inc. $1,375.00 09/10/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681284
Principal investigator 1 Genentech, Inc. $1,375.00 09/10/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681336
Principal investigator 1 Genentech, Inc. $1,375.00 09/10/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681346
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 09/04/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388125
Principal investigator 1 Epizyme, Inc. $1,125.00 09/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281306
Principal investigator 1 Genentech, Inc. $29,358.00 09/03/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211677474
Principal investigator 1 Daiichi Sankyo Inc. $885.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387449
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387451
Principal investigator 1 Daiichi Sankyo Inc. $5,078.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387453
Principal investigator 1 Genentech, Inc. $861.00 08/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680433
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327109
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940148
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940164
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940171
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940177
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940190
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940200
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940209
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940224
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940237
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940248
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940262
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940272
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940282
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940293
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940305
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940316
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940326
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940342
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940353
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940365
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940406
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940431
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940449
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940467
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940476
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940492
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940504
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940516
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940526
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 08/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754192
Principal investigator 1 Daiichi Sankyo Inc. $490.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387447
Principal investigator 1 Genentech, Inc. $511.00 08/06/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680513
Principal investigator 1 Genentech, Inc. $14,650.00 08/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211677419
Principal investigator 1 Genentech, Inc. $26,384.00 08/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211677451
Principal investigator 1 Genentech, Inc. $173.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680279
Principal investigator 1 Genentech, Inc. $1,500.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680307
Principal investigator 1 Genentech, Inc. $2,093.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680331
Principal investigator 1 Genentech, Inc. $319.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680361
Principal investigator 1 Genentech, Inc. $536.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680413
Principal investigator 1 Genentech, Inc. $536.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680463
Principal investigator 1 Genentech, Inc. $536.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680471
Principal investigator 1 Genentech, Inc. $114.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680527
Principal investigator 1 Genentech, Inc. $2,022.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680567
Principal investigator 1 Genentech, Inc. $70.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680739
Principal investigator 1 Genentech, Inc. $373.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680885
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 07/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327184
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $411.79 07/28/2025 Non-covered Recipient Entity
Coastal Pharmacy, Llc
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235997964
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680327
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680449
Principal investigator 1 Genentech, Inc. $23,095.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680481
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680551
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680555
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680629
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680675
Principal investigator 1 Genentech, Inc. $114.00 07/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680825
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,750.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185537443
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753540
Principal investigator 1 Incyte Corporation $956.00 07/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CTR DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591771
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940381
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940394
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940418
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327406
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329086
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/19/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387445
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753350
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940553
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940582
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 06/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940900
Principal investigator 1 ABBVIE INC. $1,094.86 05/16/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202485379
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,240.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753104
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,835.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753108
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,835.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753110
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $1,620.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753132
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $230.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753134
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753136
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387443
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388279
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388281
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388283
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388285
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388287
Principal investigator 1 Daiichi Sankyo Inc. $236.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388289
Principal investigator 1 Daiichi Sankyo Inc. $412.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388291
Principal investigator 1 Daiichi Sankyo Inc. $1,416.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388293
Principal investigator 1 Daiichi Sankyo Inc. $82.60 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388295
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388297
Principal investigator 1 Daiichi Sankyo Inc. $177.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388299
Principal investigator 1 Daiichi Sankyo Inc. $2,360.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388301
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 05/15/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223388303
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940541
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940564
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940605
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940618
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940643
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940655
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940666
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940678
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940686
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940715
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940766
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940775
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940788
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940801
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940812
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940823
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940841
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940859
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940872
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940887
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940915
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940926
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 05/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940953
Principal investigator 1 Genentech, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680007
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 05/08/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388305
Principal investigator 1 Genentech, Inc. $13,562.00 05/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211677205
Principal investigator 1 AstraZeneca Pharmaceuticals LP $92,628.70 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185537433
Principal investigator 1 Genentech, Inc. $3,742.00 05/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211680175
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,650.00 04/30/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185537429
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,288.61 04/30/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185537437
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,050.00 04/30/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185537439
Principal investigator 1 Daiichi Sankyo Inc. $8,000.00 04/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388121
Principal investigator 1 Daiichi Sankyo Inc. $5,282.00 04/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388123
Principal investigator 1 ABBVIE INC. $5,518.28 04/23/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202478724
Principal investigator 1 ABBVIE INC. $1,250.00 04/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202478129
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753006
Principal investigator 1 Daiichi Sankyo Inc. $588.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387441
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388119
Principal investigator 1 ABBVIE INC. $1,063.00 04/15/2025 Non-covered Recipient Entity
COASTAL PHARMACY-ORALS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202476618
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383856
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383860
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CTR DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591764
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CTR DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591767
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940728
Principal investigator 1 Epizyme, Inc. $2,557.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280928
Principal investigator 1 Epizyme, Inc. $3,539.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280988
Principal investigator 1 Epizyme, Inc. $1,958.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281004
Principal investigator 1 Epizyme, Inc. $1,596.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281034
Principal investigator 1 Epizyme, Inc. $2,145.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281038
Principal investigator 1 Epizyme, Inc. $1,005.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281052
Principal investigator 1 Epizyme, Inc. $1,005.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281128
Principal investigator 1 Epizyme, Inc. $1,831.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281150
Principal investigator 1 Epizyme, Inc. $2,076.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281152
Principal investigator 1 Epizyme, Inc. $2,785.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281160
Principal investigator 1 Epizyme, Inc. $1,958.00 04/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281162
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387437
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387439
Principal investigator 1 Daiichi Sankyo Inc. $66.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388083
Principal investigator 1 Daiichi Sankyo Inc. $236.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388117
Principal investigator 1 Genentech, Inc. $1,375.00 03/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Polarix No dispute reported 06/30/2026 1211681242
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388033
Principal investigator 1 Daiichi Sankyo Inc. $64.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388053
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388057
Principal investigator 1 Daiichi Sankyo Inc. $50.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388107
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388113
Principal investigator 1 Amgen Inc. $1,500.15 03/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246648422
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 03/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383982
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940594
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940630
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940701
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174940752
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754208
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388041
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388047
Principal investigator 1 Daiichi Sankyo Inc. $51.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388055
Principal investigator 1 Daiichi Sankyo Inc. $59.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388059
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388063
Principal investigator 1 Daiichi Sankyo Inc. $53.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388081
Principal investigator 1 Daiichi Sankyo Inc. $64.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388087
Principal investigator 1 Daiichi Sankyo Inc. $40.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388091
Principal investigator 1 Daiichi Sankyo Inc. $50.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388095
Principal investigator 1 Daiichi Sankyo Inc. $42.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388103
Principal investigator 1 Genentech, Inc. $1,475.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679813
Principal investigator 1 Genentech, Inc. $1,500.00 03/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679849
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388029
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388031
Principal investigator 1 Daiichi Sankyo Inc. $53.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388035
Principal investigator 1 Daiichi Sankyo Inc. $51.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388037
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388039
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388043
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388045
Principal investigator 1 Daiichi Sankyo Inc. $555.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388049
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388051
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388061
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388065
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388067
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388069
Principal investigator 1 Daiichi Sankyo Inc. $66.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388071
Principal investigator 1 Daiichi Sankyo Inc. $42.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388073
Principal investigator 1 Daiichi Sankyo Inc. $302.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388075
Principal investigator 1 Daiichi Sankyo Inc. $40.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388077
Principal investigator 1 Daiichi Sankyo Inc. $65.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388079
Principal investigator 1 Daiichi Sankyo Inc. $211.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388085
Principal investigator 1 Daiichi Sankyo Inc. $66.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388089
Principal investigator 1 Daiichi Sankyo Inc. $3,415.13 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388093
Principal investigator 1 Daiichi Sankyo Inc. $59.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388097
Principal investigator 1 Daiichi Sankyo Inc. $368.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388099
Principal investigator 1 Daiichi Sankyo Inc. $54.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388101
Principal investigator 1 Daiichi Sankyo Inc. $40.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388105
Principal investigator 1 Daiichi Sankyo Inc. $51.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388109
Principal investigator 1 Daiichi Sankyo Inc. $1,416.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388111
Principal investigator 1 Daiichi Sankyo Inc. $301.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388115
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383868
Principal investigator 1 Daiichi Sankyo Inc. $150.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383870
Principal investigator 1 Daiichi Sankyo Inc. $4,047.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383872
Principal investigator 1 Daiichi Sankyo Inc. $500.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383874
Principal investigator 1 Daiichi Sankyo Inc. $70.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383876
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383878
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383880
Principal investigator 1 Daiichi Sankyo Inc. $2,006.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383882
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383884
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383886
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383888
Principal investigator 1 Daiichi Sankyo Inc. $1,204.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383890
Principal investigator 1 Daiichi Sankyo Inc. $752.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383892
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383894
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383896
Principal investigator 1 Daiichi Sankyo Inc. $4,515.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383898
Principal investigator 1 Daiichi Sankyo Inc. $350.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383900
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383902
Principal investigator 1 Daiichi Sankyo Inc. $36.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383912
Principal investigator 1 Daiichi Sankyo Inc. $43.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383914
Principal investigator 1 Daiichi Sankyo Inc. $50.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383918
Principal investigator 1 Daiichi Sankyo Inc. $45.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383920
Principal investigator 1 Daiichi Sankyo Inc. $43.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383922
Principal investigator 1 Daiichi Sankyo Inc. $34.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383926
Principal investigator 1 Daiichi Sankyo Inc. $55.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383930
Principal investigator 1 Daiichi Sankyo Inc. $46.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383936
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383946
Principal investigator 1 Daiichi Sankyo Inc. $1,749.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383976
Principal investigator 1 Daiichi Sankyo Inc. $56.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383978
Principal investigator 1 Daiichi Sankyo Inc. $201.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383980
Principal investigator 1 Daiichi Sankyo Inc. $54.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383984
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 02/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383992
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387191
Principal investigator 1 Daiichi Sankyo Inc. $7,014.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387193
Principal investigator 1 Daiichi Sankyo Inc. $8,915.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387195
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,200.00 02/11/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER No dispute reported 06/30/2026 1235992209
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754182
Principal investigator 1 Genentech, Inc. $4,847.00 01/22/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211679869
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $338.35 01/21/2025 Covered Recipient Teaching Hospital
Ascension Sacred Heart Pensacola
A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR214), Versus Nivolumab Alone Versus Standard of Care in Participants With MuscleInvasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible No dispute reported 06/30/2026 1236001809
Principal investigator 1 Eli Lilly and Company $119,574.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891996
Principal investigator 1 AstraZeneca Pharmaceuticals LP $142,228.92 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185537431
Principal investigator 1 Daiichi Sankyo Inc. $7,733.00 01/16/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388277
Principal investigator 1 ABBVIE INC. $1,063.00 01/15/2025 Non-covered Recipient Entity
COASTAL PHARMACY-ORALS
Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma No dispute reported 06/30/2026 1202438599
Principal investigator 1 Amgen Inc. $516.77 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
MyLung Consortium Study (USOR) No dispute reported 06/30/2026 1246648428
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,860.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185537435
Principal investigator 1 Daiichi Sankyo Inc. $1,874.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383864
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U304 No dispute reported 06/30/2026 1223383866
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383904
Principal investigator 1 Daiichi Sankyo Inc. $40.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383906
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383908
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383910
Principal investigator 1 Daiichi Sankyo Inc. $40.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383916
Principal investigator 1 Daiichi Sankyo Inc. $418.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383924
Principal investigator 1 Daiichi Sankyo Inc. $43.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383928
Principal investigator 1 Daiichi Sankyo Inc. $54.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383932
Principal investigator 1 Daiichi Sankyo Inc. $46.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383934
Principal investigator 1 Daiichi Sankyo Inc. $56.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383938
Principal investigator 1 Daiichi Sankyo Inc. $45.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383940
Principal investigator 1 Daiichi Sankyo Inc. $34.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383942
Principal investigator 1 Daiichi Sankyo Inc. $43.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383944
Principal investigator 1 Daiichi Sankyo Inc. $2,039.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383948
Principal investigator 1 Daiichi Sankyo Inc. $46.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383950
Principal investigator 1 Daiichi Sankyo Inc. $3,415.13 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383952
Principal investigator 1 Daiichi Sankyo Inc. $54.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383954
Principal investigator 1 Daiichi Sankyo Inc. $45.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383956
Principal investigator 1 Daiichi Sankyo Inc. $55.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383958
Principal investigator 1 Daiichi Sankyo Inc. $50.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383960
Principal investigator 1 Daiichi Sankyo Inc. $383.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383962
Principal investigator 1 Daiichi Sankyo Inc. $40.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383964
Principal investigator 1 Daiichi Sankyo Inc. $55.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383966
Principal investigator 1 Daiichi Sankyo Inc. $43.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383968
Principal investigator 1 Daiichi Sankyo Inc. $56.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383970
Principal investigator 1 Daiichi Sankyo Inc. $36.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383972
Principal investigator 1 Daiichi Sankyo Inc. $34.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383974
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383986
Principal investigator 1 Daiichi Sankyo Inc. $50.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383990
Principal investigator 1 Daiichi Sankyo Inc. $43.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383994
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $935.00 01/15/2025 Non-covered Recipient Entity
Southern Cancer Center
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER No dispute reported 06/30/2026 1235993583
Principal investigator 1 Eli Lilly and Company $114,463.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187888100
Principal investigator 1 Eli Lilly and Company $2,383.30 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
Not supplied No dispute reported 06/30/2026 1187889674
Principal investigator 1 Eli Lilly and Company $4,221.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187891356
Principal investigator 1 Incyte Corporation $956.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER-DAPHNE
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240591761
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 01/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940739
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 01/15/2025 Non-covered Recipient Entity
Southern Cancer Center
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174940937
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,063.00 01/15/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
Clinical trial to assess the efficacy and safety of an alternative dosing regimen of ribociclib in breast cancer No dispute reported 06/30/2026 1190303823
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753344
Principal investigator 1 Eli Lilly and Company $2.67 01/07/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891324
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/03/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383988
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/03/2025 Non-covered Recipient Entity
SOUTHERN CANCER CENTER, P.C.
DS1062-A-U303 No dispute reported 06/30/2026 1223383996